Biogen (BIIB) awards 7,390 restricted stock units to product strategy head

Rhea-AI Filing Summary

Izzar Rachid reported acquisition or exercise transactions in this Form 4 filing.

BIOGEN INC. executive Rachid Izzar, Head of Global Product Strategy, received a grant of 7,390 restricted stock units. These RSUs were awarded at no cash cost per unit and represent a form of stock-based compensation that aligns the executive’s interests with shareholders.

The restricted stock units vest in three equal yearly installments, beginning on the first anniversary of the February 13, 2026 grant date. The entire 7,390-unit award is reported as directly owned following the transaction.

Insights

Equity Compensation Analyst

Biogen grants 7,390 RSUs to a senior executive as routine equity compensation.

BIOGEN INC. awarded 7,390 restricted stock units to Rachid Izzar, its Head of Global Product Strategy. The transaction is recorded as a grant or award acquisition with a stated price per unit of $0.0000, indicating no cash payment by the executive for this equity-based compensation.

The RSUs vest in three equal yearly installments starting on the first anniversary of the February 13, 2026 grant date, creating a multi-year retention and incentive structure. This type of award is a common component of senior executive pay and does not, by itself, signal a change in the company’s financial outlook.

Future company filings may show how many of these RSUs ultimately vest and convert into shares, depending on continued service and any applicable conditions. For now, this represents a standard equity grant designed to align management with shareholder value over time.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Izzar Rachid

Role Head of Global Product Strat.

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Unit	7,390	$0.00	--

Holdings After Transaction: Restricted Stock Unit — 7,390 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Izzar Rachid

(Last) (First) (Middle)

225 BINNEY STREET

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOGEN INC. [ BIIB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Head of Global Product Strat.

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	$0	02/13/2026		A		7,390		(1)	02/13/2029	Common Stock	7,390	$0	7,390	D

Explanation of Responses:

1. The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026.

	/s/ Wendell Taylor, attorney-in-fact for Rachid Izzar	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Biogen (BIIB) report for Rachid Izzar?

Biogen reported that executive Rachid Izzar received a grant of 7,390 restricted stock units. This equity award is classified as a grant or award acquisition and is recorded as directly owned, reflecting standard stock-based compensation for a senior leader.

How many restricted stock units were granted to the Biogen (BIIB) executive?

Rachid Izzar received 7,390 restricted stock units from Biogen. The Form 4 shows all 7,390 units as directly owned after the transaction, with no cash paid per unit, highlighting their role as a compensation award rather than an open-market purchase.

What is the vesting schedule for Rachid Izzar’s Biogen (BIIB) RSU grant?

The 7,390 restricted stock units vest in three equal yearly installments. Vesting begins on the first anniversary of the grant date of February 13, 2026, creating a three-year incentive and retention period tied to Izzar’s continued service with Biogen.

Was Rachid Izzar’s Biogen (BIIB) RSU grant a buy or a grant?

The transaction is a grant or award acquisition, not an open-market buy. The Form 4 classifies it under code A, with a transaction price per unit of $0.0000, indicating stock-based compensation granted by Biogen rather than shares purchased by the executive.

What role does the insider receiving RSUs at Biogen (BIIB) hold?

The recipient, Rachid Izzar, serves as Biogen’s Head of Global Product Strategy. Granting 7,390 restricted stock units to this role aligns a key leader’s compensation with long-term shareholder value through equity that vests over three years starting February 13, 2026.